Long Ideas - Data from the Closest Competition, It Turns Out, Support Sarepta Accelerated approval aside, the chatter regarding Sarepta Therapeutics (SRPT) in the past week has centered … Continue Reading
Read NowLong Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read NowMost Popular - PropThink kicked off the week by revisiting Endo Health (ENDP) and brought the scoop on Rajiv De Silva’s materializing plans for the company. De Silva, … Continue Reading
Read NowLong Ideas - Navidea Biopharmaceuticals (NAVB) delivered a surprise to investors with earlier-than expected top-line interim results from the company’s NEO3-06 trial, which demonstrated Lymphoseek’s ability to identify … Continue Reading
Read NowLong Ideas - Since our report on Alexion Pharmaceuticals (ALXN) in early December, shares are virtually flat; outperformance through mid-January has been replaced by underperformance as expectations of … Continue Reading
Read NowLong Ideas - The spotlight has been on Astex Pharmaceuticals (ASTX) in the last month, and as investors have taken notice of the oncology developer, shares have rallied … Continue Reading
Read NowLong Ideas - As we wrote last week, Endo Health’s (ENDP) newly appointed CEO and former Valeant (VRX) operating star Rajiv De Silva is on the road with … Continue Reading
Read Now